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INTRODUCTION
Bioequivalence	 tests	 are	 a	 way	 to	 evaluate	
the	 efficacy	 of	 a	 drug.	 In	 the	 bioequivalence	
study	 a	 number	 of	 closely	 related	 parameters	
are	evaluated	(Ognean	et al.,	2008).	Among	these	
parameters	 are	 the	 time	 to	 peak	 concentration	
(Tmax),	 representing	 the	necessary	 time	needed	
for	 the	 active	 substance	 to	 reach	 the	 maximum	
concentration	 in	 blood	 or	 the	 necessary	 time	
needed	for	the	active	substance	to	reach	it’s	half-
life	 (T
1/2
).	 These	 parameters	 are	 determined	
according	to	the	maximum	absorbed	substance	in	
the	body	(Cristina	and	Chirciu,	2010).
AIM AND OBJECTIVES
The	 study	 aims	 to	 evaluate	 and	 compare	
the	 necessary	 time	 to	 attain	 the	maximum	 drug	
concentration	 in	 the	 blood	 (T
max
)	 and	 to	 assess	
the	 half-time	 (T
1/2
)	 of	 praziquantel	 in	 two	 drug	
formulations,	in	a	bioequivalence	study.	
MATERIAL AND METHODS
In	the	study,	12	cats	of	European	breed	were	
included,	 clinically	healthy,	 coming	 from	rural	or	
urban	 environment.	 The	 cats	 were	 admitted	 for	
testing	according	to	a	series	of	inclusion/exclusion	
criteria.	Each	 subject	was	 submitted	 to	an	 initial	
screening,	consisting	of	clinical,	hematological	and	
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AbstractT
max
 represents	the	amount	of	time	necessary	to	achieve	the	maximum	concentration	of	the	drug	in	the	systemic	
circulation.	The	half	 time	of	a	drug	represents	the	mandatory	time	required	to	reduce	the	drugs	concentration	
from	the	plasma	to	half,	after	reaching	a	steady	state.
Evaluating	and	comparing	the	time	to	attain	the	maximum	drug	concentration	in	the	blood	(T
max
)	and	to	assess	
the	half-time	(T
1/2
)	of	praziquantel	in	two	drug	formulations,	in	a	bioequivalence	study.	These	measurements	were	
carried	out	with	regard	to	the	peak	concentration	(C
max
)	of	the	drugs.	In	the	study,	were	included	12	healthy	cats,	
of	European	breed.	According	to	the	study	protocol,	the	cats	received	praziquantel,	in	a	dosage	of	20	mg,	in	two	
phases,	at	different	time	periods,	for	three	consecutive	days.	A	series	of	parameters	were	determined,	including	T
max
,	T
1/2
,	and		C
max
.	It	was	observed	that,	at	the	same	amount	of	praziquantel	(20	mg),	the	results	were	different.	
For	the	first	group,	the	maximum	substance	concentration	was	at	1.18	±	0.4	hours	and	for	the	second	group,	was	
at	1.27	±	0.26	hours.	The	half-time	was	at	1.07	±	0.22	hours	for	the	first	group	while	for	the	second	group	was	at	
1.84	±	1.16	hours.	The	results	of	the	investigated	parameters	revealed	mainly	individual	differences,	which	were	
situated	within	the	bioequivalence	standards.
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biochemical	tests.	The	bioequivalence	testing	was	
performed	in	two	phases,	separated	by	a	washout	
period	of	14	days.	In	each	stage	the	cats	received	
a	drug	containing	either	20	mg	(TEST)	or	50	mg	
(REFERENCE)	of	praziquantel.	The	administration	
of	 tablets	 was	 performed	 according	 to	 a	
randomization	 list.	After	drug	administration,	11	
blood	samples	were	collected	from	each	cat,	over	a	
three	days	period,	at	predetermined	times.
RESULTS AND DISCUSSIONS
The	analysis	of	the	chemical	composition	of	the	
two	tested	formulas,	displayed	that,	regarding	the	
active	formula	praziquantel,	the	quantity	from	the	
two	products	was	not	even.	Thus,	the	REFERENCE	
product	 contained	 50	mg	 and	 the	 TEST	 product	
contained	20	mg. The	results	recorded	for	C
max	
and	T
1/2
	had	individual	variations,	consistent	with	the	
drug	 administered	 (test	 or	 reference)	 however	
without	 statistical	 significance. Regarding	 the	
results	obtained	 for	 the	maximum	concentration	
(C
max
),	 there	 are	 observed	 fluctuations	 of	 the	
individual	values	and	also	variations	of	the	mean	
results	 obtained	 (Fig.1).	 Thus,	 for	 the	 TEST	
product,	 a	mean	 value	 of	 1250.58	 ±	 607.53	 ng/
mL	 was	 obtained,	 with	 a	 maximum	 of	 2423.21	
ng/mL	and	a	minimum	of	356.96	ng/mL.	For	the	
REFERENCE	 product,	 the	 mean	 recorded	 value	
was	 925.78	 ±	 515.39	 ng/mL,	 with	 a	 maximum	
value	of	1823.89	ng/mL	and	a	minimum	value	of	
184.68	ng/mL.
For	 the	 products	 half-life,	 as	 it	 can	 be	
noticed	 in	 Fig.	 2,	 only	 minor	 fluctuations	 of	 the	
individual	 results	 were	 recorded.	 This	 aspect	 is	
more	noticeable	 for	 the	 test	product,	were	 small	
variations	 of	 the	 individual	 results	 were	 noted	
with	regard	to	the	mean	value	(1.08	±	0.21	h).	The	
values	recorded	 for	 the	reference	product	varied	
slightly,	the	recorded	mean	being	of	1.77	±	1.13	h.	
Correlating	the	results	with	the	maximum	time	of	
absorption	(1.16	±	0.38	h	 for	the	tested	product,	
and	1.25	±	0.26	h	for	the	reference	product)	it	can	
be	 stated	 that	 the	 tested	 product	 is	 much	more	
rapidly	absorbed	in	the	blood	stream,	in	a	higher	
concentration,	being	also	eliminated	faster.
CONCLUSION
Since	 the	 two	 products	 had	 a	 different	 con-
centration	 of	 praziquantel,	 the	 individual	 re-
sults	 obtained	 indicate	 that	 there	 are	 variable	
fluctuations	 between	 the	 two	 products.	 The	
results	show	that	the	tested	product	is	absorbed	in	
a	higher	quantity	in	the	cats	body,	having	a	shorter	
half-life	and	thus	being	eliminated	faster.
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Fig.1.	Individual	variations	of	the	C
max
    Fig.2.	Individual	results	for	T
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